Stay updated on Extension Study of Upadacitinib in Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the Extension Study of Upadacitinib in Atopic Dermatitis Clinical Trial page.

Latest updates to the Extension Study of Upadacitinib in Atopic Dermatitis Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check19 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1.0%
- Check26 days agoNo Change Detected
- Check33 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1.0%
- Check40 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check54 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check62 days agoChange DetectedThe latest update includes the posting of results for a Phase 3b study on Upadacitinib for atopic dermatitis, with detailed data on treatment-emergent adverse events and laboratory values, while previous entries have been removed, including earlier results and some site information.SummaryDifference31%
- Check91 days agoChange DetectedThe website has been updated from version 2.13.2 to 2.13.3.SummaryDifference0.1%
Stay in the know with updates to Extension Study of Upadacitinib in Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Extension Study of Upadacitinib in Atopic Dermatitis Clinical Trial page.